The Manufacturers Life Insurance Company Buys 2,450 Shares of Annexon, Inc. (NASDAQ:ANNX)

The Manufacturers Life Insurance Company increased its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 1.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 159,586 shares of the company’s stock after buying an additional 2,450 shares during the quarter. The Manufacturers Life Insurance Company owned 0.15% of Annexon worth $945,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in Annexon by 221.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock worth $4,335,000 after purchasing an additional 504,656 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Annexon by 9.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,160,886 shares of the company’s stock worth $6,872,000 after purchasing an additional 96,085 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Annexon in the 3rd quarter valued at approximately $154,000. Mutual of America Capital Management LLC grew its position in shares of Annexon by 3.1% in the 3rd quarter. Mutual of America Capital Management LLC now owns 659,254 shares of the company’s stock valued at $3,903,000 after acquiring an additional 19,681 shares during the period. Finally, GSA Capital Partners LLP increased its stake in shares of Annexon by 10.7% during the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after purchasing an additional 3,355 shares during the last quarter.

Annexon Stock Down 7.6 %

Shares of Annexon stock opened at $4.51 on Friday. The stock has a market cap of $480.74 million, a price-to-earnings ratio of -4.30 and a beta of 1.10. Annexon, Inc. has a twelve month low of $2.34 and a twelve month high of $8.40. The company’s fifty day moving average is $6.39 and its 200 day moving average is $5.97.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ANNX shares. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $15.80.

Insider Transactions at Annexon

In related news, EVP Ted Yednock sold 5,408 shares of Annexon stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total transaction of $40,073.28. Following the sale, the executive vice president now directly owns 71,365 shares in the company, valued at approximately $528,814.65. This trade represents a 7.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.67% of the stock is currently owned by insiders.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.